- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03238599
Pedometer Activity Monitoring After ASCT (PAMAL)
Clinical Trial Investigating Pedometer-based Activity Monitoring After Autologous Transplantation in Lymphoma and Myeloma Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
Patient-reported outcome measures (PROMs) Cancer patients experience significant physical and psychosocial consequences of cancer and treatment which affect quality of life (QoL). These consequences may be under-recognized and under-treated in oncology practice, resulting in greater morbidity that is costly to patients and the health system. Patient-reported outcome measures (PROMs) are advocated for use in routine cancer clinical practice for early detection of distress and as a performance metric for evaluating the quality of care on health outcomes.
A PROM is defined as 'any report coming directly from the patient about a health condition and its treatment using a self-reported measure. PROMs focus on physical symptoms, treatment toxicities, psychosocial problems or global health-related quality of life (HRQoL) impacts of a health condition. PROMs that capture the whole-person impact of cancer and treatments on health outcomes are increasingly recommended by patients, clinicians, and decision makers.
A number of implementation issues related to the use of PROMs data need to be considered: (i) limiting data collection so as to minimize patient burden and completion time, (ii) collecting PROM data at baseline and selected follow-up times while minimizing the number of assessments, (iii) considering whether measurement equivalence has been established when using different modes of patient-reported data collection (e.g. web, telephone, tablet, or paper), (iv) collecting data via electronic technologies whenever possible, and (v) employing methods to minimize missing data including educating site personnel, patients and clinicians, and real-time monitoring of adherence.
Step counting devices to monitor physical activity The intensive medical treatment of patients with hematologic malignancies is associated with numerous long-term adverse effects, including anemia, fatigue, and reduced physical exercise capacity. Patients with hematologic malignancies may benefit from physical exercise programs in terms of maintenance or even improvement in fatigue, physical activity, and fitness levels. Since many patients with hematologic malignancies are young and professionally active, regaining physical activity is a prerequisite for timely resuming professional activities, and, thus, of immediate socio-economic relevance. A major component of daily physical activity and the most common form of exercise is walking. Walking is self-regulated in intensity, duration, and frequency, and it can be an important indicator of a person's health and fitness status. The improvement of functional status is a primary goal in the rehabilitation of cancer patients. It is thus crucial to be able to document quantitatively the walking activity of patients who are recovering from intensive medical treatment. An understanding of the quantity (or lack) of walking activity seems particularly important in addressing the needs of cancer patients who are recovering from intensive medical treatment
Patients with hematologic malignancies recovering from intensive medical treatment such as after high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) can benefit from gradually regaining a more physically active lifestyle, typically by increasing ambulatory activity. Step counting devices (accelerometers and pedometers) offer an opportunity to monitor daily ambulatory activity. Tudor-Locke and Bassett originally proposed a graduated step index to describe pedometer-determined habitual physical activity in adults:
- < 5,000 steps/day (sedentary);
- 5,000-7,499 steps/day (low active);
- 7,500-9,999 steps/day (somewhat active);
- ≥ 10,000-12,499 steps/day (active); and
- ≥12,500 steps/day (highly active).
Recognizing a considerable floor effect (i.e., insensitivity to the range of activity levels below the lowest threshold) when applied to low active populations, Tudor-Locke et al suggested that the original sedentary level is further divided into two additional incremental levels:
< 2,500 steps/day (basal activity) and 2,500- 4,999 steps/day (limited activity).
Prospective use of PROMs and step counting devices after ASCT The investigators here propose a non-randomized prospective non-blinded non-interventional observational clinical phase II study, assessing physical activity in myeloma and lymphoma patients following high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT). The primary objective is to determine whether regaining a daily activity of at least 5'000 steps (thus, regaining the "low active" level) 30 days after HDCT with ASCT is associated with a higher probability to resume professional activity.
The hypothesis will be that 50% or more of those patients who achieve >5'000 steps during one day at least once between 10 and 30 days after ASCT will have resumed their professional activities at the day 100 assessment, whereas only 30% of those patients, who have not achieved the 5'000 steps threshold until day 30, will have restarted their professional life at the day 100 assessment. Physical activity will be assessed by a web-based pedometer device, and patient-reported outcome measures (PROMs) will be collected using a web-based tool.
The MIDATA.coop platform The trial will use the MIDATA.coop platform based on the principle of citizen-controlled data storage and sharing. MIDATA.coop embodies an IT platform managing personal data and the governance needed to operate it. As a not-for-profit citizen-owned cooperative, its vision is to allow citizens to collect, store, visualize, and share specific sets of their personal data with friends and health professionals, and to make anonymized versions of part of these data accessible to research projects in fields that appeal to them. The value generated by this secondary use of personal data is managed collectively to operate and extend the platform and support further research projects.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Thomas Pabst, MD
- Phone Number: +41 31 632 84 30
- Email: thomas.pabst@insel.ch
Study Locations
-
-
-
Berne, Switzerland, 3010
- Departement of Medical Oncology, University Hospital Berne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with plasma cell disorders (myeloma and amyloidosis) or with lymphomas (NHL and Hodgkin) undergoing high-dose chemotherapy with autologous stem cell transplantation.
- Patients must be aged 18-65 years.
- Patients must have given voluntary written informed consent.
- Patients without professional activity (such as due to early retirement, dependency on disability reimbursement, or unemployment) are eligible.
Exclusion Criteria:
- Patients with other serious medical condition that could potentially interfere with the completion of treatment according to this protocol.
- Lack of patient cooperation to allow study treatment as outlined in this protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pedometer-based activity monitoring
The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
|
Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Professional Activity
Time Frame: 100 days
|
Number of patients who resumed their professional activity within 100 days after ASCT.
|
100 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical activity
Time Frame: 100 days
|
Web-based patient reported physical activity assessed by digital step counting after autologous transplant.
|
100 days
|
Febrile Episodes
Time Frame: 100 days
|
Web-based patient reported febrile episodes after autologous transplant.
|
100 days
|
Well-being
Time Frame: 100 days
|
Web-based patient reported well-being assessed by digital follow-up reporting after autologous transplant.
|
100 days
|
Collaborators and Investigators
Investigators
- Study Chair: Thomas Pabst, MD, Departement of Medical Oncology, University Hospital Berne
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PAMAL trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Clinical Trials on Pedometer-based activity monitoring after ASCT
-
Federal University of Juiz de ForaCompleted
-
University of California, San DiegoCompletedBreast CancerUnited States
-
University of California, San FranciscoCompletedPhysical Activity | Sedentary Lifestyle | Pre-DiabeticUnited States
-
University of California, San FranciscoNational Institute of Nursing Research (NINR); American Heart AssociationWithdrawnPhysical Activity | Sedentary LifestyleUnited States
-
Pennington Biomedical Research CenterOur Lady of the Lake Regional Medical Center; American Council on ExerciseCompletedPediatric Obesity | Weight Loss
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI); American Heart AssociationCompletedPhysical Activity | Sedentary LifestyleUnited States
-
University of Erlangen-NürnbergBad Reichenhall Clinic, Center for Rehabilitation, Pulmonology and Orthopedics and other collaboratorsCompletedChronic Obstructive Pulmonary Disease (COPD)Germany
-
Mayo ClinicNot yet recruitingMultiple MyelomaUnited States
-
University of TennesseeNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedObesity | OverweightUnited States
-
Copenhagen University Hospital, HvidovreUniversity of Copenhagen; Sygekassernes Helsefond; The Danish Rheumatism Association and other collaboratorsRecruitingOsteoarthritis, KneeDenmark